Administration of erythropoietin on telaprevir/PEG-IFN/RBV triple combination therapy in HCV patients with low pre-treatment hemoglobin levels.

Administration of erythropoietin on telaprevir/PEG-IFN/RBV triple combination therapy in HCV patients with low pre-treatment hemoglobin levels. - Administration of erythropoietin on telaprevir/PEG-IFN/RBV triple combination therapy in HCV patients with low pre-treatment hemoglobin levels.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007919

Enrollment

Registered

2012-05-10

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

Administration of erythropoietin ITPA genotype

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients over 20 years of age 2) Pre-treatment hemoglobin level is below 13 g/dl 3) HCV patients with serogroup 1 and high viral load 4) Patients with IL28B and ITPA genotypes determined

Exclusion criteria

Exclusion criteria: 1) Patients over 70 years of age 2) Patients with liver cirrhosis 3) Patients with hepatocellular carcinoma or other malignancies 4) Patients co-infected with HIV or HBV 5) Patients judged by doctor that participation in the study is improper

Design outcomes

Primary

Measure	Time frame
Adherence of telaprevir/PEG-IFN/RBV triple combination therapy up to 12 weeks	—

Secondary

Measure	Time frame
1) Change of hemoglobin level 2) Differences of treatment efficacy depending on IL28B or ITPA genotypes 3) Correlation between drug adherence of telaprevir/PEG-IFN/RBV and treatment efficacy 4) Ratio of discontinuation and treatment duration of telaprevir/PEG-IFN/RBV 5) Correlation between viral mutation and treatment efficacy 6) Correlation between drug adherence and telaprevir-resistant viral mutation 7) Correlation between telaprevir-resistant viral mutation and plasma concentration of telaprevir 8) Difference of treatment efficacy depending on administration of erythropoietin	—

Measure

Time frame

1) Change of hemoglobin level 2) Differences of treatment efficacy depending on IL28B or ITPA genotypes 3) Correlation between drug adherence of telaprevir/PEG-IFN/RBV and treatment efficacy 4) Ratio of discontinuation and treatment duration of telaprevir/PEG-IFN/RBV 5) Correlation between viral mutation and treatment efficacy 6) Correlation between drug adherence and telaprevir-resistant viral mutation 7) Correlation between telaprevir-resistant viral mutation and plasma concentration of telaprevir 8) Difference of treatment efficacy depending on administration of erythropoietin

—

Countries

Japan

Contacts

Public ContactKentaro Matsuura

Nagoya City University, Graduate School of Medical Sciences Department of Gastroenterology and Metabolism

keifuji@med.nagoya-cu.ac.jp052-853-8211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026